HI
DYN icon

Harbour Investments’s Dyne Therapeutics DYN Stock Holding History

Harbour Investments’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9
Closed – – 2904
2021
Q3 		$0 Sell
9
-5
-36% -$89 ﹤0.01% 3792
2021
Q2 		$0 Sell
14
-1
-7% -$19 ﹤0.01% 3812
2021
Q1 		$0 Buy
+15
New +$290 ﹤0.01% 3624

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbour Investments's DYN Position: Q4 2021 in Review

Harbour Investments sold out of Dyne Therapeutics (DYN) in Q4 2021, closing a stake of 9 shares.

Harbour Investments first reported a position in DYN in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 93 funds tracked by Wall St. Rank hold DYN as of Q4 2021.

  • Harbour Investments reported no remaining Dyne Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 9 Dyne Therapeutics shares in Q4 2021.
  • Harbour Investments first reported a position in Dyne Therapeutics in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Dyne Therapeutics position peaked at $0 in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.